BIOCRYST PHARMACEUTICALS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BCRX in the last 30 days.
See all $BCRX insider activity →Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
BioCryst Pharmaceuticals, with a market cap under $5B, reported profitability and plans to expand through acquisitions in the rare disease space. Its FDA-approved drug Orladeyo generated over $2B in sales, with $645M forecasted for 2023. CEO Charlie Gayer aims to leverage the company's financial stability to acquire early-stage assets, targeting smaller peak sales potentials.
BioCryst Pharmaceuticals (BCRX) received Japanese approval for ORLADEYO in pediatric HAE patients aged 2 to under 12. This is the first oral prophylactic therapy for children in Japan, supported by APeX-P trial data. BCRX stock closed at $9.68, up 1.36%, and is trading at $9.72 in pre-market.
Over the past 7 days, alphai's AI scored 3 news stories mentioning BCRX (BIOCRYST PHARMACEUTICALS INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent BCRX coverage spans earnings, financial news and regulation.
International clearance broadens market reach, likely positive for BCRX.
Positive guidance and potential M&A pipeline could lift the stock, especially after a 25% YTD rally.
Regulatory win expands market opportunity in Japan and may boost sales and share price.
Profitability and accelerating revenue strengthen the case for a strategic buyer, but the article does not confirm any deal.
The call combines improving ORLADEYO commercial metrics with a cost-structure reset and a new external innovation model, which should support near-term margin expectations.
alphai scores every news story that mentions BCRX with an AI model for sentiment and relevance, and aggregates insider trades from BIOCRYST PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readBioCryst Pharmaceuticals, with a market cap under $5B, reported profitability and plans to expand through acquisitions in the rare disease space. Its FDA-approved drug Orladeyo generated over $2B in sales, with $645M forecasted for 2023. CEO Charlie Gayer aims to leverage the company's financial stability to acquire early-stage assets, targeting smaller peak sales potentials.
3 min readBioCryst Pharmaceuticals (BCRX) received Japanese approval for ORLADEYO in pediatric HAE patients aged 2 to under 12. This is the first oral prophylactic therapy for children in Japan, supported by APeX-P trial data. BCRX stock closed at $9.68, up 1.36%, and is trading at $9.72 in pre-market.
2 min readBioCryst Pharmaceuticals (BCRX) reported its first full year of profitability in 2025. In Q2 2026, revenue rose 34% to $218.25 million, with $98.47 million operating income and $352.57 million in cash and short-term investments. The company’s HAE drug Orladeyo generated $158.2 million in Q2. Takeda (TAK) is cited as a potential acquirer due to navenibart’s impact on Takhzyro.
6 min readBioCryst (BCRX) discussed its Q2 2026 earnings call, citing ORLADEYO revenue of $158.2M, up 10% year-on-year, and total revenue up 45% excluding the European divestiture. Paid therapy rate rose to 84% from 83% a year earlier. The company said it completed enrollment of the ALPHA-ORBIT pivotal study for navenibart, with top-line data expected in Q3 2027, and reported $113.2M non-GAAP operating profit and $350M+ cash.
7 min readBioCryst Pharmaceuticals said it will permanently close its Birmingham-area Discovery Center of Excellence and discontinue internal drug discovery. A WARN filing dated Aug. 4 shows layoffs of 47 employees at its Hoover facility starting Oct. 7. The company cut 2026 non-GAAP operating expense guidance to $420 million to $440 million and plans to keep advancing navenibart and BCX17725.
4 min readBioCryst Pharmaceuticals reported Q2 2026 results driven by ORLADEYO capsule demand, with total revenue up 45% YoY excluding divested European operations. Management said it ended internal drug discovery and closed its Birmingham unit. Full-year 2026 ORLADEYO guidance remains $625M to $645M. Cash and investments were over $350M.
6 min readBIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO reve
6 min readBioCryst Pharmaceuticals (Nasdaq: BCRX) appointed David W. Jenkins as Chief Scientific Officer, effective immediately, reporting to Chief R&D Officer Sandeep Menon. Jenkins previously led external innovation at Ipsen and oversaw adding 35+ assets to its pipeline. The role focuses on using partnerships to accelerate rare-disease therapies. BioCryst also cites ORLADEYO (berotralstat) commercialization.
3 min readBiotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).
7 min read
